P-CD19CD20-ALLO1 for B-Cell Malignancies
This study is testing a new immunotherapy called P-CD19CD20-ALLO1, which uses special immune cells (CAR-T cells) to fight certain B-cell cancers. It's for people aged 18 and older who have specific types of B-cell lymphoma, such as Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma Grade 3B, that have returned or are not responding to other treatments. The main goal is to find the safest dose of P-CD19CD20-ALLO1 and understand any side effects. You would receive P-CD19CD20-ALLO1 as a single intravenous (IV) infusion, and you might also receive another drug called Rimiducid. This study is currently enrolling 120 participants.
- Study design
- This is a Phase 1 study with two parts: a dose-escalation phase to find the maximum tolerated dose (MTD) and an expansion phase. It is an open-label study, meaning both you and your doctors will know what treatment you are receiving.
- What's involved
- After joining, you will receive lymphodepletion therapy before a single IV administration of P-CD19CD20-ALLO1. Your safety, tolerability, and response will be measured regularly.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be assessed from baseline through 28 days after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
At a glance
Conditions
Where it's being run
16 sites across 14 statesStudy leadership
- Simon Heidegger, MD · STUDY_DIRECTOR · Lead Medical Director, Oncology, Genentech Research Early Development
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Assess the safety and MTD or RDE of P-CD19CD20-ALLO1 based on dose limiting toxicities (DLT)Baseline through 28 days
Rate of DLT's